Status:
COMPLETED
Effect of Levamisole Supplementation on Tetanus Vaccination Response Rates in Hemodialysis Patients
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
Renal Dialysis
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
Brief Summary
Levamisole as an immunomodulator drug has been demonstrated to improve the immune response to Hepatitis B virus (HBV) vaccination in hemodialysis patients. The aim of this study was to evaluate the ef...
Detailed Description
Levamisole as an immunomodulator drug has been demonstrated to improve the immune response to HBV vaccination in hemodialysis patients. The aim of this study was to evaluate the effect of levamisole s...
Eligibility Criteria
Inclusion
- being under regular hemodialysis for more than 3 months
- unprotective baseline levels of antitetanus IgG
Exclusion
- tetanus diphtheria (Td) vaccination in past year
- leukopenia (WBC\<1500 cells/mcL)
- immunosuppressive drug exposure in past 2 months
- recent hospitalization or history of transfusion of blood products in the past 3 months.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00705692
Start Date
March 1 2008
End Date
November 1 2008
Last Update
July 26 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faghihi Hospital Hemodialysis Center, Shiraz University of Medical Sciences
Shiraz, Fars, Iran, 1978 - 71345